ARTICLE | Company News
JHL Biotech Inc. (TPex-E:6540) granted Sanofi (Euronext:SAN: NYSE:SNY) rights in China to develop and commercialize biosimilar rituximab (JHL1101), as well as options for rights to other JHL candidates. JHL is to receive $21 million up front and is eligible for $236 million in milestones, plus royalties.
Sanofi also invested NT$2.6 billion ($79.6 million) in JHL by purchasing 28.3 million shares at NT$90 in a separate private placement...